Aadi bioscience presents clinical data from precision 1 and ampect trials at the society of gynecological oncology (sgo) annual meeting on women's cancer

Los angeles , march 26, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today announced that it presented data from its precision 1 and ampect trials in two posters at the society of gynecological oncology (sgo) annual meeting 2023, taking place march 25-28, 2023, in tampa, fl. "we are pleased to present additional data with nab-sirolimus from our ampect trial and highlight our precision 1 trial at sgo 2023, which is the premier medical meeting focused on advancing research for gynecologic cancer," said loretta itri, md.
AADI Ratings Summary
AADI Quant Ranking